-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-03-27
Values as of: 2024-03-27
The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Pharmaceutical IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of pharmaceutical companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 23 U.S. pharmaceuticals companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Company Website : www.invescopowershares.com
Currency: USD
Country : USA
Inception Date: 23/06/2005
Primary Benchmark: Dynamic Pharmaceutical Intellidex TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.57%
Management Expense Ratio: 0.56 %
N/A
N/A
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
N/A |
USD 37.76B |
| VHT | Vanguard Health Care Index Fun.. | 0.10 % |
N/A |
USD 16.98B |
| XBI | SPDR® S&P Biotech ETF | 0.35 % |
N/A |
USD 7.05B |
| IHI | iShares U.S. Medical Devices E.. | 0.43 % |
N/A |
USD 5.55B |
| IXJ | iShares Global Healthcare ETF | 0.46 % |
N/A |
USD 4.11B |
| IYH | iShares U.S. Healthcare ETF | 0.43 % |
N/A |
USD 3.23B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
N/A |
USD 2.94B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
N/A |
USD 1.33B |
| FBT | First Trust NYSE Arca Biotechn.. | 0.57 % |
N/A |
USD 1.08B |
| IHF | iShares U.S. Healthcare Provid.. | 0.43 % |
N/A |
USD 0.82B |
N/A
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 5.49% | 50% | F | 61% | D- | ||
| Dividend Return | 0.22% | 54% | F | 10% | F | ||
| Total Return | 5.72% | 55% | F | 58% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 6.85% | 41% | F | 47% | F | ||
| Dividend Return | 0.98% | 58% | F | 11% | F | ||
| Total Return | 7.84% | 41% | F | 39% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 23.19% | 40% | F | 59% | D- | ||
| Dividend Return | 3.46% | 53% | F | 10% | F | ||
| Total Return | 26.65% | 45% | F | 51% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 6.48% | 45% | F | 64% | D | ||
| Dividend Return | 7.05% | 41% | F | 59% | D- | ||
| Total Return | 0.57% | 55% | F | 15% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 13.23% | 73% | C | 73% | C | ||
| Risk Adjusted Return | 53.29% | 64% | D | 80% | B- | ||
| Market Capitalization | 0.91B | 41% | F | 38% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
